AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion" is generating significant coverage in the Business category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Whalesbook, GuruFocus, RAPS.org and The Business Journals. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 95d ago.
Quick answers
Why is "AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (11)
- AbbVie paying $10.9B to buy Waltham biotech NBC Boston · 95d ago
- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal Yahoo Finance · 95d ago
- Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron's · 95d ago
- AbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business Daily · 95d ago
- AbbVie sharpens immunology focus with $10.9 billion Apogee deal Reuters · 95d ago
- AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal The Boston Globe · 95d ago
- Done deal: AbbVie to buy Apogee for $10.9B FirstWord Pharma · 95d ago
- US Stocks Steady Near Record Highs; AbbVie to Buy Apogee for $10.9 Billion Whalesbook · 95d ago
- AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree GuruFocus · 95d ago
- Recon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapy RAPS.org · 95d ago
- AbbVie seals $10.9 billion deal to acquire biotech Apogee Therapeutics The Business Journals · 95d ago
Topics
Related trends
Former Dallas 'We Buy Ugly Houses' franchisee sentenced to federal prison for investment scam - FOX 4 News Dallas-Fort Worth
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
US to Buy Back Up to $6 Billion in Longer-Dated Treasuries
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A $950 Million Reason to Buy SpaceX Stock
4 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
Should You Buy Micron Stock Before Its Next Earnings Report?
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
What immunologists do to avoid colds and flu in autumn
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Updated: Electra says $350M IPO will help it become a commercial biotech
Immunology drugmaker Electra Therapeutics pursues an upsized $350 million initial public offering on Nasdaq under the ticker ETRA.